For years, products containing concentrated, semi-synthetic variants of kratom have been marketed as natural alternatives, despite carrying significant risks associated with opioid-like effects. Shatterproof leadership described the DEA’s move as a long-overdue intervention against the rapid proliferation of substances that have evaded standard regulatory scrutiny.
In section Releases
Shatterproof Backs DEA Move to Schedule Kratom Derivative 7-OH
The Drug Enforcement Administration’s decision to temporarily schedule 7-hydroxymitragynine and related compounds marks a critical shift in federal oversight. By targeting these potent, chemically modified substances, regulators are finally catching up to a marketplace that has long outpaced existing safety safeguards for consumers, particularly among younger populations.
While the scheduling is a step toward greater oversight, the organization maintains that federal authorities must expand their focus to encompass the broader landscape of synthetic and highly concentrated kratom derivatives. Future policy efforts should prioritize establishing clear product standards, strengthening enforcement against misleading marketing, and funding rigorous scientific research. Shatterproof intends to keep advocating for evidence-based policies that restrict youth access to these emerging drugs while promoting transparency regarding the safety and efficacy of all kratom-related products.
Comments (0)
No comments yet. Be the first!